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Abstract	
We	need	greater	understanding	of	the	mechanisms	underlying	protection	against	influenza	virus	
to	develop	more	effective	vaccines.	To	do	this,	we	need	better,	more	reproducible	methods	of	
sampling	the	nasal	mucosa.	The	aim	of	the	current	study	was	to	compare	levels	of	influenza	virus	
A	subtype-specific	 IgA	collected	using	three	different	methods	of	nasal	sampling.	Samples	were	
collected	 from	 healthy	 adult	 volunteers	 before	 and	 after	 LAIV	 immunization	 by	 nasal	 wash,	
flocked	swabs	and	Synthetic	Absorptive	Matrix	(SAM)	strips.	Influenza	A	virus	subtype-specific	IgA	
levels	were	measured	by	haemagglutinin	binding	ELISA	or	haemagglutinin	binding	microarray	and	
the	functional	response	was	assessed	by	microneutralization.	Nasosorption	using	SAM	strips	lead	
to	 the	 recovery	of	 a	more	 concentrated	 sample	of	material,	with	 a	 significantly	higher	 level	of	
total	 and	 influenza	 H1-specific	 IgA.	 However,	 an	 equivalent	 percentage	 of	 specific	 IgA	 was	
observed	with	all	sampling	methods	when	normalised	to	the	total	IgA.	Responses	measured	using	
a	 recently	 developed	 antibody	 microarray	 platform,	 which	 allows	 evaluation	 of	 binding	 to	
multiple	 influenza	 strains	 simultaneously	with	 small	 sample	 volumes,	were	 compared	 to	ELISA.	
There	 was	 a	 good	 correlation	 between	 ELISA	 and	microarray	 values.	Material	 recovered	 from	
SAM	 strips	was	weakly	 neutralizing	when	 used	 in	 an	 in	 vitro	 assay,	with	 a	modest	 correlation	
between	the	level	of	IgA	measured	by	ELISA	and	neutralization,	but	a	greater	correlation	between	
microarray-measured	 IgA	and	neutralizing	activity.	 In	conclusion	we	have	tested	three	different	
methods	of	nasal	 sampling	and	show	that	 flocked	swabs	and	novel	SAM	strips	are	appropriate	
alternatives	to	traditional	nasal	washes	for	assessment	of	mucosal	influenza	humoral	immunity.		
	
	 	
1 Introduction	
Whether	acquired	through	natural	infection	or	vaccination	with	live	attenuated	influenza	vaccine	
(LAIV),	 antibody-mediated	 protection	 at	 mucosal	 surfaces	 is	 thought	 to	 play	 a	 key	 role	 in	
preventing	influenza	infections1.	 In	particular	 IgA	at	mucosal	surfaces	has	been	shown	to	play	a	
role	 in	 reducing	 viral	 shedding2.	 To	 support	 the	 assessment	 of	 mucosal	 influenza	 vaccines	 in	
future	 clinical	 trials	 and	 studies	 of	 naturally-acquired	 mucosal	 immunity,	 standardized	 sample	
collection	 methods	 from	 nasal	 mucosal	 lining	 fluid	 (MLF)	 are	 required	 that	 acceptable	 to	
participants	 (especially	 young	 children)	 and	 collect	 consistent	MLF	 volumes.	 Furthermore,	 the	
volume	 collected	 and	 concentration	 of	 influenza-specific	 antibodies	 should	 be	 sufficient	 to	
measure	mucosal	responses	to	all	influenza	strains	included	in	the	vaccine.	These	aspects	are	also	
dependent	 on	 the	 requirements,	 performance	 and	 sensitivity	 of	 the	 IgA	 assay	 used,	 which	
traditionally	has	been	based	on	ELISA	techniques.		
	
We	present	 the	 results	of	a	pilot	 study	assessing	different	methods	 for	 collecting	nasal	MLF	 to	
detect	both	total	and	influenza-specific	IgA:	(i)	nasal	wash,	the	method	traditionally	used	for	this	
purpose	 but	 challenging	 in	 young	 children	 and	 subject	 to	 erratic	 sample	 recovery	 (ii)	 flocked	
swabs	and	(iii)	synthetic	absorptive	matrix	(SAM)	strips.	We	also	compare	a	highly	sensitive	ELISA	
modified	 from	 previous	 studies2,3	 and	 a	 novel	 protein	 microarray	 requiring	 minimal	 sample	
volume,	adapted	to	measure	influenza-specific	IgA4.	
2 Materials	and	Methods	
2.1.	 Subjects,	vaccination	and	mucosal	lining	fluid	sampling	methods	
Thirteen	healthy	adult	volunteers	(age	25	-	44	years,	8	male,	5	female)	were	recruited	following	
written	 informed	 consent	 at	 the	 Clinical	 Research	 Facility,	 Sheffield	 Teaching	 Hospitals	 NHS	
Foundation	Trust,	Sheffield,	UK.	Ethical	approval	was	granted	by	the	Leeds	East	National	Research	
Ethics	Service	Committee.	Nasal	MLF	was	sampled	immediately	prior	to	vaccination	with	2015/16	
seasonal	tetravalent	LAIV	(Fluenz	Tetra,	Astra	Zeneca,	UK)	and	28	days	later	via	three	methods:	(i)	
Flocked	swabs	(Copan	Diagnostics	Inc.,	Murrieta,	CA,	USA)	(ii)	SAM	strips	(Hunt	Diagnostics,	UK)	
and	(iii)	Nasal	washes	using	the	Naclerio	method5.	A	day	28	post-vaccine	timepoint	was	chosen	
due	 to	 prior	 studies	 showing	 a	 mucosal	 IgA	 response	 to	 LAIV	 in	 both	 children	 and	 adults	 at	
approximately	1	month	after	vaccination6,7.	Subjects	were	administered	tetravalent	LAIV	into	the	
nasal	 cavity	 (0.1ml	 per	 nostril).	 This	 vaccine	 contained	 the	 haemagglutinin	 (HA)	 and	
neuraminidase	 (NA)	 from	 a	A/California/7/2009	 (H1N1)	 pdm09-like	 strain	 (A/Bolivia/559/2013)	
and	 A/Switzerland/9715293/2013	 (H3N2)	 as	 the	 two	 influenza	 A	 antigens	 on	 the	 A/Ann	
Arbor/6/60	attenuated	backbone.		
	
2.2	 Sample	collection	and	processing		
All	samples	were	collected	by	one	operator,	processed	within	3	hours	of	collection	and	stored	at	-
70˚C.	The	order	of	sample	collection	(nasal	swab,	strip,	wash)	was	kept	consistent	at	all	visits	with	
approximately	15	minute	 intervals	 in	between.	Sample	processing	was	undertaken	according	to	
already	 established	 protocols	 using	 these	 methods.	 Nasal	 swabs	 were	 inserted	 into	 the	 nasal	
cavity	 and	 repeatedly	 rotated	 360˚	 for	 approximately	 5	 seconds.	 Secretions	 were	 eluted	 by	
centrifugation	at	4˚C	through	a	Costar®	spin-X®	tube	(0.22µm	pore	size,	Sigma,	UK)	pre-incubated	
with	 300µl	 of	 extraction	 buffer	 (EB:	 phosphate	 buffered	 saline	 (PBS)	 containing	 0.02%	 sodium	
azide	 and	 0.25M	NaCl).	 Repeat	 centrifugation	with	 a	 further	 300µl	 of	 EB	was	 performed.	One	
swab	from	each	nostril	was	obtained	and	eluted	material	pooled.	A	single	SAM	strip	was	inserted	
into	a	patent	nostril	 according	 to	 the	manufacturer’s	 instructions	 for	60	 seconds.	Material	was	
eluted	in	300µl	of	EB	by	centrifugation	as	detailed	above.	Material	from	one	nostril	at	day	0	and	
both	nostrils	(processed	separately)	at	day	28	were	obtained.	Nasal	washes	were	obtained	using	
the	Naclerio	method5,	by	instilling	10ml	of	sterile	0.9%	NaCl	into	each	nostril	 in	turn	and	asking	
the	subject	to	expel	forcefully	into	a	sterile	container.	Collected	material	was	centrifuged	at	4˚C	
and	supernatant	stored	at	-70˚C.		
	
2.3	 Enzyme-linked	Immunosorbent	Assays	(ELISA)	
2.3.1	 Total	IgA	ELISA	
An	ELISA	was	modified	from	previously	described	methods	used	to	detect	anti-HIV-1	antibodies	
8,9.	ELISA	plates	(medium	binding,	Greiner	Bio-One)	were	coated	1:1	with	anti-Human	kappa	and	
anti-Human	 lambda	 capture	 antibodies	 (Southern	 Biotech,	UK)	 at	 4˚C	 for	 16	 –	 18	 hours.	 After	
washing	in	PBS-T	(PBS	with	0.05%	Tween®20	(Sigma,	UK)),	plates	were	blocked	with	assay	buffer	
(AB;	 1:1	 Casein	 blocking	 buffer	 (Thermofisher	 scientific,	 UK)	 and	 PBS)	 for	 1	 hour	 at	 37˚C.	MLF	
samples	were	diluted	1:1,000,	1:5,000	and	1:25,000	and	incubated	for	1	hour	at	37˚C	in	triplicate,	
along	with	 a	 serial	 dilution	 of	 human	 IgA	 (from	 colostrum,	 Sigma,	 UK)	 to	 generate	 a	 standard	
curve	(range	200ng/ml	to	0.195ng/ml).	After	washing	with	PBS-T,	 IgA	antibodies	were	detected	
using	 biotin-labelled	 Goat	 anti-human	 IgA	 (Insight	 Biotechnology	 Ltd,	 UK)	 followed	 by	
streptavidin-poly-HRP40	 (2BScientific,	 UK)	 and	 signal	 developed	 using	 SureBlue	 TMB	Microwell	
Peroxidase	 Substrate	 and	 TMB	 Stop	 solution	 (both	 from	 Insight	 Biotechnology	 Ltd,	 UK).	 After	
development,	 plates	 were	 read	 at	 450nm	 using	 a	 VersaMax	 plate	 reader.	 Generation	 of	 the	
standard	 curve	 and	 total	 IgA	quantification	 in	 samples	was	performed	 following	 subtraction	of	
background	optical	density	 (OD)	values.	 	A	mean	estimated	 IgA	value	of	dilutions	 falling	within	
the	 linear	 portion	 of	 the	 standard	 curve	 were	 included	 in	 final	 calculations.	 Some	 SAM	 strip-
collected	material	 required	 further	 dilution	 to	 1:125,000	 to	 obtain	OD	 values	within	 the	 linear	
portion	of	the	standard	curve.	
	
2.3.2	 Influenza-specific	IgA	ELISA	
ELISA	plates	were	coated	with	recombinant	HA	from	either	A/California/7/2009	(full	 length	HA)	
or	A/Switzerland/9715293/2013	H3N2	(HA1)	at	2.0µg/ml	(Sino	Biological,	China)	at	4˚C	for	16	–	
18	hours.	After	washing	and	blocking	steps	as	above,	MLF	samples	were	incubated	neat,	at	1:5,	
1:25	 or	 1:125	 dilution	 in	 triplicate	 for	 1	 hour	 at	 37˚C.	 IgA	 detection,	 development	 and	
quantification	using	an	IgA	standard	curve	was	performed	as	described	above.		
	
2.4	 Haemagglutinin	Microarray	to	detect	anti-influenza	IgA	antibodies	
A	previously	described	HA	microarray	designed	to	profile	anti-influenza	IgG	antibodies	in	human	
sera4	 was	 adapted	 to	 detect	 anti-influenza	 IgA	 in	 MLF	 samples.	 Briefly,	 nitrocellulose	 coated	
slides	 (ONCYTE®	 AVID,	 Grace	 Bio-Labs,	 USA)	 were	 spotted	 in	 duplicate	 with	 recombinant	 HA1	
protein	 from	 both	 A/California/6/2009	 (H1N1pdm09)	 and	 A/Brisbane/10/2007	 (H3N2).	 These	
were	used	 to	detect	anti-influenza	 IgA	 in	40	operator-blinded	samples	 (consisting	of	day	0	and	
day	 28	 swab	 and	 strip-eluted	 material	 from	 10	 subjects).	 Slides	 were	 treated	 with	 Blocker™	
BLOTTO	blocking	buffer	(Thermo	Fisher	Scientific,	USA)	for	1	hour	at	37˚C.	After	washing,	samples	
were	 diluted	 1:3	 and	 transferred	 to	 the	 arrays.	 Following	 incubation	 for	 1	 hour	 at	 37˚C,	 slides	
were	washed	 and	 incubated	with	 goat	 anti-human	 IgA	 conjugated	with	Dylight649-fluorescent	
dye	(Jackson	ImmunoResearch,	USA)	for	a	further	1	hour	at	37˚C.	After	washing,	slides	were	dried	
and	signals	quantified	by	a	PowerScanner™	microarray	scanner	(Tecan	Trading	AG,	Switzerland).	
Mean	 spot	 fluorescence	 foreground	 intensity	 was	 determined	 by	 using	 ScanArray®	 Express	
software	(PerkinElmer,	USA).		
		
2.5		 Influenza	microneutralization	assays	
MLF	from	SAM	strip-eluted	material	was	tested	by	standard	methods	using	a	microneutralization	
(MN)	assay	as	described	previously10,	with	egg-cultured	A/California/7/2009	H1N1pdm09	virus.	
Briefly,	samples	were	heat	inactivated	for	30	min	at	56˚C	and	2-fold	serial	dilutions	from	1:10	to	
1:320	 in	50µl	volume	of	PBS	 (in	duplicate)	were	mixed	with	an	equal	volume	of	 influenza	virus	
previously	titrated	on	Madin-Darby	canine	kidney	(MDCK)	cells.	After	a	1-hour	incubation	at	room	
temperature,	100µl	of	MDCK	cells	at	5	x	105/ml	was	added	to	each	well	and	plates	incubated	for	
16	–	18	hours	at	37	˚C.	Monolayers	were	washed	and	fixed	in	cold	methanol/H202	(0.6%)	for	30	
minutes.	The	presence	of	influenza	nucleoprotein	(NP)	was	detected	by	ELISA	with	a	monoclonal	
antibody	to	the	influenza	A	NP	as	described	previously11,12.	MN	titres	were	calculated	as	the	MLF	
dilution	at	which	50%	reduction	in	the	virus-infected	to	uninfected	optical	density	(OD)	ratio	was	
seen.		
	
2.6 Statistical	analyses	
Based	 on	 a	 previous	 study	 comparing	 allergen-specific	 IgA	 detection	 in	 SAM	 strips	 and	 nasal	
washes13,	we	 calculated	 that	 5	participants	would	be	 sufficient	 to	detect	 a	 2-fold	difference	 in	
anti-influenza	 IgA	 levels	 at	 day	 28	 post-LAIV	 between	 these	 two	methods	 (power	 90%,	 alpha	
0.01).	To	account	for	a	proportion	of	subjects	without	detectable	IgA	and	potential	dropouts,	we	
aimed	 to	 recruit	 10	 –	 15	 participants.	 All	 statistical	 analyses	 were	 performed	 using	 GraphPad	
Prism	 version	 5.0	 for	Macintosh.	 Differences	 in	 IgA	 levels	 among	 the	 three	 sampling	methods	
were	 investigated	 using	 the	 Friedman’s	 test.	 The	 non-parametric	 pairwise	multiple	
comparisons	procedure,	 Dunn’s	 test,	 was	 used	 for	 post-hoc	 comparison	 whenever	 the	 null	
hypothesis	 was	 rejected	 based	 on	 Friedman’s	 test.	 Correlation	 analyses	 were	made	 using	 the	
Spearman’s	rank	correlation	coefficient.		
	
3 Results	
	
3.1	 The	yield	of	total	and	H1pdm09-specific	IgA	is	greater	in	SAM	strips	compared	to	flocked	
swabs	or	nasal	washes	
Approximately	2	–	18ml	from	nasal	washes,	1.2ml	from	flocked	swabs	and	300µl	from	SAM	strip	
collected	fluid	was	available	for	assays.	Considering	both	day	0	and	day	28	values	(n	=	26),	total	
IgA	concentration	was	4	–	6	fold	higher	in	SAM	strip-collected	material	compared	to	flocked	swab	
or	nasal	wash	material:	median	(inter-quartile	range,	IQR)	348.0µg/ml	(171.4,	509.3),	78.3µg/ml	
(32.3,	 137.0)	 and	 55.9µg/ml	 (24.5,	 90.4)	 respectively.	 H1pdm09	 HA-specific	 IgA	 concentration	
was	approximately	5-fold	higher	 in	SAM	strip-collected	material:	median	118.1ng/ml	 (IQR	40.9,	
259.7),	 23.4ng/ml	 (7.1,	 64.9)	 and	25.4ng/ml	 (11.1,	 35.4)	 in	 SAM	 strip,	 swab	and	wash	 samples	
respectively.	 	Significant	differences	between	sampling	methods	are	shown	in	Figure	1a	and	1b.	
Total	IgA	values	for	each	subject	were	more	consistent	across	visits	in	flocked	swab	and	SAM	strip	
samples	than	nasal	wash	samples,	with	a	significant	correlation	seen	between	day	0	and	day	28	
total	IgA	quantities	for	each	subject	in	samples	collected	by	swab	and	strip	(Figure	1c	-	e).	Finally,	
total	IgA	quantities	in	samples	collected	from	left	and	right	nares	using	SAM	strips	at	day	28	were	
compared	 and	 no	 significant	 difference	 found	 (median	 335.0	 vs	 228.7µg/ml,	 p	 =	 0.45),	 with	 a	
good	correlation	between	the	two	(rs	0.736,	p	=	0.002)(data	not	shown).		
	
3.2 Standardization	of	H1pdm09-specific	IgA	to	total	IgA	results	in	comparable	values	
between	sampling	methods	
To	account	for	variability	in	the	volume	of	MLF	collected	across	subjects	and	visits,	H1pdm09	HA-
specific	IgA	quantities	were	expressed	as	a	percentage	of	total	IgA.	These	were	more	comparable	
between	 nasal	 swabs	 and	 SAM	 strips	 than	 raw	 values	 at	 both	 day	 0	 and	 day	 28	 (Fig	 2).	 	 The	
percentage	H1pdm09	HA-specific	 IgA	 in	nasal	washes	was,	however,	significantly	higher	than	 in	
flocked	swabs	at	day	28.	This	may	reflect	the	trend	towards	a	greater	yield	of	total	IgA	in	swabs	
compared	 to	 washes	 (Fig	 1a).	 A	 good	 correlation	 is	 seen	 between	 percentage	 H1pdm09	 HA-
specific/total	 IgA	 values	 between	methods	 in	 each	 subject	 (Fig	 3),	 with	 the	 most	 comparable	
being	 flocked	 swab	 and	 SAM	 strips,	 again	 suggesting	 that	 these	 are	 more	 comparable	 and	
consistent	methods	of	MLF	collection.		
	
3.3 Comparison	of	haemagglutinin	microarray	and	ELISA	to	detect	anti-influenza	IgA	and	the	
mucosal	response	to	LAIV		
A	disadvantage	of	ELISA	is	the	sample	volume	required	per	antigen	tested,	making	it	challenging	
to	measure	antibodies	to	all	antigens	 included	 in	seasonal	 influenza	vaccines.	HA	microarray4	 is	
able	to	reliably	detect	anti-influenza	IgG	in	very	small	quantities	of	serum	(10µl),	so	we	tested	the	
ability	of	this	assay	to	detect	anti-influenza	IgA	in	MLF.	Due	to	sample	volume	availability,	H3	HA-
specific	 IgA	ELISAs	were	only	performed	on	 flocked	swab	 (and	not	SAM	strip)	material.	A	good	
correlation	 was	 seen	 between	 both	 H1pdm09	 HA	 and	 H3	 HA	 influenza-specific	 IgA	 levels	
(fluorescence	units)	in	the	HA	microarray	and	IgA	quantified	by	ELISA	in	ng/ml	(Fig	4).	This	was	in	
spite	 of	 a	 mismatch	 in	 H3	 HA	 antigen	 in	 the	 microarray	 slides	 prepared	 for	 a	 previous	 study	
(A/Brisbane/10/2007)	and	that	of	the	vaccine	antigen	(A/Switzerland/9715293/2013).		
	
To	assess	the	mucosal	 IgA	response	to	LAIV,	the	fold	difference	was	calculated	between	day	28	
and	day	0	samples	in	influenza-specific	IgA	measured	by	ELISA	and	HA	microarray	for	each	subject	
(in	 each	 case	 normalized	 by	 the	 total	 IgA	 quantity).	 A	 ≥2-fold	 increase	 was	 considered	 a	
significant	response	as	defined	in	a	previous	LAIV	study6.	This	was	undertaken	for	swab	samples	
in	 the	 10	 subjects	 for	 whom	 comparable	 H1pdm09	 and	 H3-specific	 data	 were	 available	
(Supplementary	Table	1).	No	 subject	 showed	a	 significant	 increase	 in	H1pdm09	HA-specific	 IgA	
post-vaccine	using	ELISA-measured	data,	with	one	subject	showing	an	H3-specific	 IgA	response.	
In	contrast,	three	subjects	showed	an	H1-specific	IgA	response	and	three	subjects	an	H3-specific	
IgA	response	to	LAIV	using	HA	microarray	measured	data	(with	two	subjects	showing	a	response	
to	both	antigens).		
	
3.4 Low	titre	influenza	microneutralization	activity	is	detectable	in	nasal	mucosal	lining	fluid	
To	 evaluate	 a	 more	 functional	 readout	 of	 anti-influenza	 activity	 in	 MLF,	 available	 SAM	 strip-
collected	material	(as	those	with	the	greatest	antibody	yield)	were	tested	in	a	standard	influenza	
microneutralization	(MN)	assay.	While	11/25	of	samples	tested	showed	detectable	titres	against	
A/California/7/2009	 H1N1pdm09	 virus,	 these	 were	 all	 low	 titre	 (1:10	 –	 1:24).	 A	 weak	 but	
significant	correlation	was	observed	between	the	reciprocal	MN	titre	and	H1pdm09	HA-specific	
IgA	value	quantified	by	ELISA	(Fig	5a).	Interestingly,	a	greater	correlation	was	observed	between	
reciprocal	MN	titres	and	H1pdm09	HA-specific	IgA	levels	(fluorescence	units)	detected	in	the	HA	
microarray	(Fig	5b).	
	
	
4 Discussion	
Reliable,	 high-yield,	 participant-acceptable	 methods	 to	 assess	 mucosal	 anti-influenza	 humoral	
activity	are	vital	 in	studies	of	both	natural	 infection	and	vaccine-induced	immunity.	We	provide	
(to	our	knowledge	for	the	first	time)	a	direct	comparison	of	nasal	washes	with	flocked	swabs	and	
SAM	 strips	 to	 collect	 MLF	 and	 measure	 influenza-specific	 IgA	 responses,	 with	 the	 latter	 two	
representing	 techniques	 with	 greater	 convenience	 for	 both	 the	 investigator	 and	 study	
participant.	
	
We	demonstrate	 that	 the	yield	of	 total	 and	 influenza-specific	 IgA	 is	 significantly	higher	 in	 SAM	
strips	 compared	 to	 flocked	 swabs	 or	 nasal	washes.	 This	 is	 in	 keeping	with	 previous	 reports	 of	
greater	cytokine13,14	and	allergen-specific	antibody13	recovery	using	SAM	strips,	but	in	contrast	to	
a	 recent	 study	 showing	 SAM	 strips	 had	 lower	 HIV-1	 antibody	 recovery	 from	 nasal	 turbinates	
compared	to	flocked	swabs8.	The	reasons	for	this	difference	are	not	clear,	but	could	include	how	
long	 SAM	 strips	 remain	 in	 contact	 with	 the	 nasal	 mucosa,	 environmental	 variation	 affecting	
mucosal	moistness	and	pre-incubation	of	Costar®	spin-X®	tubes	with	elution	buffer,	all	of	which	
may	 affect	 antibody	 yield.	 Despite	 the	 known	 variability	 of	 nasal	 IgA	 secretion	 (including	
diurnally15),	 we	 also	 observed	 a	 significant	 correlation	 between	 day	 0	 and	 day	 28	 total	 IgA	
recovery	 for	 each	 subject	 in	 flocked	 swab	 and	 SAM	 strip	 samples,	 but	 not	 nasal	 washes.	 This	
supports	 the	 hypothesis	 that	 swabs	 and	 SAM	 strips	 are	 more	 consistent	 sample	 collection	
methods	compared	to	washes.		
	
Given	 the	 small	 volumes	 of	 nasal	 MLF	 obtainable,	 sensitive	 assays	 are	 required	 to	 measure	
influenza-specific	 humoral	 immunity	 in	 these	 samples.	 One	 potential	 drawback	 of	 ELISA	 is	 the	
high	volume	of	sample	required,	especially	 if	 low	antibody	 levels	necessitate	 running	undiluted	
material	and	IgA	specific	to	several	antigens	are	measured.	We	therefore	evaluated	the	ability	of	
a	 protein	 microarray4	 to	 detect	 nasal	 influenza-specific	 IgA	 and	 demonstrated	 an	 excellent	
correlation	with	 ELISA	 data.	 Furthermore,	 this	 assay	was	 able	 to	 quantify	 IgA	 (in	 fluorescence	
units)	 in	samples	with	a	wide	range	of	ELISA-quantified	 IgA	values	 (2.7ng/ml	–	1437ng/ml)	at	a	
single	sample	dilution	 (1:3),	 thus	reducing	the	potential	errors	 introduced	by	requiring	multiple	
different	dilutions	across	 samples	 to	 fall	within	a	 range	detectable	by	ELISA.	 This	methodology	
warrants	 further	assessment	 in	 larger	 studies	and	has	 the	potential	 to	 simultaneously	measure	
not	only	anti-HA	IgA	against	several	influenza	type	A	subtypes	and	influenza	B	lineages,	but	also	
against	other	antigenic	targets	such	as	neuraminidase.		
	
We	 also	 sought	 to	 measure	 functional	 responses	 in	 SAM	 strip	 samples	 by	 using	 a	 standard	
influenza	MN	assay.	Although	neutralizing	antibody	was	detected	in	44%	of	samples	tested,	titres	
were	 low,	 suggesting	 that	 this	 is	not	a	 suitable	method	 to	assess	 functional	 responses	 in	nasal	
MLF	despite	the	higher	antibody	yield	 in	SAM	strip	samples.	We	found	only	a	weak	correlation	
between	ELISA-quantified	influenza-specific	IgA	and	MN	titres.	While	this	could	be	due	to	the	lack	
of	precision	in	MN	titres	at	such	a	restricted	range,	it	could	also	be	explained	by	varying	degrees	
of	functional	activity	in	binding	IgA	antibodies,	which	may	limit	the	spread	of	budding	virus	from	
the	cell,	rather	than	classical	entry	inhibiting	neutralization16.	IgG,	unmeasured	in	this	study,	may	
make	 a	 more	 significant	 contribution	 to	 neutralization	 measured	 by	 the	 in	 vitro	 assay	 used.	
Interestingly,	the	correlation	between	MN	activity	and	H1pdm09	influenza-specific	IgA	detected	
in	 the	microarray	was	 greater.	Whether	microarray-detected	 IgA	 levels	 are	 a	 better	 surrogate	
marker	 of	 neutralizing	 activity	 in	 nasal	 MLF	 than	 ELISA-quantified	 values	 requires	 further	
investigation.	 There	 remains	 a	 need	 to	 combine	 a	 functional	 assay	 with	 a	 convenient	 MLF	
sampling	method.		
	
Finally,	 although	 the	main	 purpose	 of	 the	 study	 was	 to	 evaluate	 sampling	methods	 and	 anti-
influenza	 IgA	detection	 assays,	we	 assessed	 the	mucosal	 IgA	 response	 to	 the	H1N1pdm09	and	
H3N2	components	in	tetravalent	LAIV	in	the	limited	sample	of	adults	in	the	study.	Using	a	≥2-fold	
increase	 from	 baseline	 post-LAIV	 as	 a	 significant	 response6,	 none	 of	 ten	 subjects	 showed	 a	
H1N1pdm09-specific	 response,	 with	 one	 subject	 showing	 a	 H3N2-specific	 response	 in	 ELISA-
measured	 influenza-specific	 IgA	 data.	 This	 is	 consistent	 with	 previous	 reports	 of	 lower	 LAIV	
efficacy	in	adults	compared	to	children17	and	poor	antibody	responses	to	H1N1pdm09	compared	
to	 H3N2	 or	 influenza	 B	 components	 in	 LAIV	 even	 in	 children18,19.	 Interestingly,	 when	 we	
considered	the	influenza-specific	IgA	data	generated	by	HA	microarray,	three	subjects	showed	a	
significant	response	to	H1	HA	and	three	subjects	to	H3	HA	(2	subjects	showed	a	≥2-fold	increase	
to	both	H1pdm09	and	H3	HA).	 It	 is	difficult	 to	 conclude	 from	 these	data	whether	 the	ELISA	or	
microarray	 data	 reflect	 a	more	 biologically	 relevant	 result	 and	 further	 studies	 are	 required	 to	
validate	the	HA	microarray	assay	in	particular.		
	
Given	the	recent	varying	effectiveness20-22	and	efficacy23,24	of	both	the	Ann	Arbor	and	Leningrad	
backbone	 LAIV	 preparations,	 there	 is	 an	 urgent	 need	 to	 conduct	 studies	 which	 incorporate	
reliable	mucosal	immunogenicity	endpoints	following	LAIV.	Studies	of	natural	influenza	infection,	
as	well	as	human	 influenza	challenge	models	can	also	enhance	our	knowledge	of	anti-influenza	
mucosal	 immunity.	We	provide	novel	data	on	both	sampling	methods	and	IgA	assays	for	use	 in	
such	studies.		
	
	
Figure	1.	SAM	strips	recover	more	concentrated	levels	of	influenza	specific	IgA.	Total	IgA	(a)	and	
H1-specific	 IgA	 (b)	 in	 nasal	 swabs,	 SAM	 strips	 and	 nasal	 washes	 quantified	 by	 indirect	 ELISA	
(Friedman	test	with	Dunn’s	posttest	for	multiple	comparisons)	at	day	0	and	day	28.	Comparisons	
include	 samples	 from	13	 subjects.	 Values	 shown	 for	 SAM	 strip	 yield	 are	 corrected	 so	 they	 are	
comparable	with	flocked	swab	yield,	given	differences	in	elution	volume	of	the	two	methods	(i.e.	
SAM	strip	values	halved	as	each	SAM	strip	was	eluted	in	300µl	while	each	nasal	swab	was	eluted	
in		600µl).	Median	and	inter-quartile	range	are	shown	for	each	dataset.	Correlation	between	the	
total	IgA	yield	at	day	0	and	day	28	from	from	each	subject	(n	=	13)	in	nasal	wash	(c),	swab	(d)	and	
SAM	strip	(e)	samples	is	shown.	SAM	=	synthetic	absorptive	material.	NS	=	not	significant.		
	
	
	
Na
sa
l s
wa
b (
da
y 0
)
SA
M 
str
ip 
(da
y 0
)
Na
sa
l w
as
h (
da
y 0
)
Na
sa
l s
wa
b (
da
y 2
8)
SA
M 
str
ip 
(da
y 2
8)
Na
sa
l w
as
h (
da
y 2
8)
0
200
400
To
ta
l I
gA
 (µ
g/
m
l)
p < 0.01 p < 0.001
NS
NS p < 0.001
NS
H
1-
sp
ec
ifi
c 
Ig
A
 (n
g/
m
l)
Na
sa
l s
wa
b (
da
y 0
)
SA
M 
str
ip 
(da
y 0
)
Na
sa
l w
as
h (
da
y 0
)
Na
sa
l s
wa
b (
da
y 2
8)
SA
M 
str
ip 
(da
y 2
8)
Na
sa
l w
as
h (
da
y 2
8)
0
50
100
150
200
250
500
600
700
800
p < 0.01 p < 0.01
NS
NS p < 0.05
NS
Day 0 Total IgA (µg/ml)
D
ay
 2
8 
To
ta
l I
gA
 (µ
g/
m
l)
0 50 100 150 200 250
0
50
100
150
200
Nasal swab
rs = 0.7498, p < 0.01
0 500 1000
0
200
400
600
800
Day 0 Total IgA (µg/ml)
D
ay
 2
8 
To
ta
l I
gA
 (µ
g/
m
l)
rs = 0.6868, p < 0.01
SAM strip
Day 0 Total IgA (µg/ml)
D
ay
 2
8 
To
ta
l I
gA
 (µ
g/
m
l)
0 100 200 300
0
50
100
150
200
rs = 0.1192, p = 0.45
Nasal wash
a b
c d e
	
	
	
	
Figure	2.	The	proportion	of	 specific	 IgA	as	a	percentage	of	 total	 IgA	 is	 constant	 regardless	of	
sampling	method.	Comparison	 of	 total	H1-specific	 IgA	 yield	 from	nasal	 swabs,	 SAM	 strips	 and	
nasal	washes,	expressed	as	a	%	of	total	IgA	detected	in	the	same	sample	at	day	0	and	28.	Values	
were	 quantified	 by	 indirect	 ELISA	 and	 comparisons	made	using	 the	 Friedman	 test	with	Dunn’s	
posttest	 for	 multiple	 comparisons.	 Overall	 Friedman	 statistic	 for	 day	 28	 samples	 was	 not	
significant,	 therefore	post-test	multiple	comparisons	were	not	performed.	Comparisons	 include	
samples	from	13	subjects.	Median	and	inter-quartile	range	are	shown	for	each	dataset.	NS	=	not	
significant.	SAM	=	synthetic	absorptive	material.		
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Figure	3.	Correlation	between	 the	H1-specific	 IgA	yield	 (expressed	as	a	%	of	 total	 IgA)	between	
different	 sampling	methods	 at	 day	 0	 (a,	 b	 and	 c)	 and	 day	 28	 (d,	 e	 and	 f).	 Comparisons	 include	
samples	from	13	subjects.	SAM	=	synthetic	absorptive	material.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Nasal swab vs nasal wash (day 0)
Nasal swab (%H1/Total IgA)
N
as
al
 w
as
h 
(%
H
1/
To
ta
l I
gA
)
0.00 0.05 0.10 0.15 0.20
0.0
0.1
0.2
0.3
rs = 0.8803, p < 0.0001
Nasal swab vs nasal wash (day 28)
0.0 0.1 0.2 0.3
0.0
0.1
0.2
0.3
N
as
al
 w
as
h 
(%
H
1/
To
ta
l I
gA
)
Nasal swab (%H1/Total IgA)
rs = 0.6226, p = 0.02
SAM strip vs nasal wash (day 0)
SAM strip (%H1/Total IgA)
N
as
al
 w
as
h 
(%
H
1/
To
ta
l I
gA
)
0.0 0.1 0.2 0.3 0.4 0.5
0.0
0.1
0.2
0.3
rs = 0.8077, p < 0.001
SAM strip vs nasal wash (day 28)
0.0 0.1 0.2 0.3
0.0
0.1
0.2
0.3
N
as
al
 w
as
h 
(%
H
1/
To
ta
l I
gA
)
SAM strip (%H1/Total IgA)
rs = 0.6924, p < 0.01
SAM strip vs nasal swab (day 0)
Nasal swab (%H1/Total IgA)
S
A
M
 s
tri
p 
(%
H
1/
To
ta
l I
gA
)
0.00 0.05 0.10 0.15 0.20
0.0
0.1
0.2
0.3
0.4
0.5
rs = 0.8391, p < 0.001
SAM strip vs nasal swab (day 28)
Nasal swab (%H1/Total IgA)
S
A
M
 s
tri
p 
(%
H
1/
To
ta
l I
gA
)
0.0 0.1 0.2 0.3
0.0
0.1
0.2
0.3
rs = 0.9145, p < 0.0001
a b c
d e f
	
Figure	 4.	 Influenza	 specific	 IgA	 levels	 detected	 are	 similar	 when	 measured	 by	 ELISA	 or	
microarray.	Correlations	 between	 H1-specific	 (a)	 and	 H3-specific	 (b)	 IgA	 in	mucosal	 lining	 fluid	
samples	detected	by	protein	microarray	and	ELISA.	H1-specific	comparisons	include	pre	and	post-
vaccine	SAM	strip	and	 flocked	swab	samples	 from	10	subjects	 (n	=	40).	H3-specific	comparisons	
include	pre	and	post-vaccine	flocked	swab	samples	from	10	subjects	(n	=	20).		
	
	
	
	
	
	
Figure	5.	IgA	recovered	from	Nasal	samples	correlates	with	neutralization.	Correlation	between	
H1-specific	 IgA	yield	 in	SAM	strips	quantified	by	ELISA	(a)	or	haemagglutinin	microarray	(b)	and	
neutralizing	activity	against	A/California/7/2009	H1N1	virus	as	assessed	in	a	microneutralization	
(MN)	assay	(a).	Samples	with	titres	<10	are	assigned	a	titre	of	1:5	for	the	purpose	of	the	analysis	
above.	
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Supplementary	Table	1.	The	H1-	and	H3-specific	IgA	response	to	LAIV	measured	by	ELISA	and	
protein	microarray.	Response	is	expressed	as	fold-change	from	day	0	(baseline)	to	day	28	after	
normalization	by	total	IgA	quantity	in	the	sample.	Shown	are	data	generated	from	flocked	swabs.	
Responses	with	≥	2-fold	increase	in	normalized	IgA	following	LAIV	are	highlighted.	
	
Subject	
Normalized	influenza-specific	
IgA	fold-change	measured	by	
ELISA	(day	28/day	0)#	
Normalized	influenza-specific	IgA	
fold-change	measured	by	
microarray	(day	28/day	0)#	 		
Total	IgA	(µg/ml)	
H1	 H3	 H1	 H3	 		 Day	0	 Day	28	
1	 1.25	 1.26	 1.81	 1.63	 		 89	 72	
2	 1.80	 1.21	 3.94	 ††	 		 9	 35	
3	 1.99	 1.72	 0.95	 0.80	 		 160	 74	
4	 1.41	 1.26	 4.02	 2.49	 		 39	 59	
5	 1.10	 1.17	 1.76	 1.17	 		 217	 98	
6	 1.25	 1.58	 2.20	 2.07	 		 128	 182	
7	 0.65	 0.84	 1.36	 1.04	 		 148	 73	
8	 0.92	 12.93	 1.02	 8.59	 		 107	 133	
9	 1.16	 †	 0.44	 0.28	 		 27	 83	
10	 1.84	 1.99	 1.43	 1.04	 		 11	 34	
#	(Specific	IgA	at	day	28	(ng/µL	in	ELISA	or	fluorescence	units	in	microarray)/total	IgA	on	day	28	(µg/ml)	
			(Specific	IgA	at	day	0	(ng/uL	in	ELISA	or	fluorescence	units	in	microarray)/total	IgA	on	day	0	(µg/ml)	
†	Unable	to	measure	fold-change	as	no	detectable	H3-specific	IgA	at	baseline.		
††	Unable	to	calculate	fold-change	as	background	corrected	fluorescence	value	negative	at	baseline.		
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